Related Experiment Video
Updated: Jul 10, 2026
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease
Abhay R Moghekar1, James A Rock2, Richard C Mohs3
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Introduction:
This study evaluated the diagnostic performance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio to detect amyloid positivity in patients with cognitive decline symptoms.
Methods:
The Lumipulse Plasma Ratio was evaluated using predetermined thresholds (≤0.00370 negative; ≥0.00738 positive) against cerebrospinal fluid (CSF) biomarker ratios or amyloid positron emission tomography (PET) imaging as references in 499 adults (≥50 years old) enrolled in prospective studies conducted across academic memory clinics and research centers.
Results:
Amyloid status was determined by CSF in 347 patients (189 positive [54.5%]) and by PET imaging in 152 patients (66 positive [43.4%]). The Lumipulse Plasma Ratio was positive in 219 patients (43.9%), negative in 182 (36.5%), and indeterminate in 98 (19.6%). Positive and negative predictive values were 91.8% and 97.3%, with a sensitivity and specificity of 97.6% and 90.8%, respectively.
Discussion:
The US Food and Drug Administration-cleared Lumipulse Plasma Ratio demonstrated high accuracy in identifying amyloid pathology and offers an alternative to CSF testing and amyloid PET imaging.
